<DOC>
	<DOCNO>NCT01188863</DOCNO>
	<brief_summary>This protocol intend compare effect solid ( tablet ) liquid oral dosage form LX4211 subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Study Two Oral Formulations LX4211 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Adults age 18 65 year age Males females nonchildbearing potential Diagnosis type 2 diabetes mellitus least 6 month prior screen Fasting plasma glucose ≤240 mg/dL Body mass index &lt; 42 kg/sq HbA1c 711 % Cpeptide ≥1.0 ng/mL Ability provide write informed consent History type 1 diabetes mellitus , diabetic ketoacidosis , hyperosmolar nonketonic syndrome , incontinence , nocturia Current use blood glucoselowering agent metformin Exposure insulin , thiazide , loop diuretic within 4 week prior screen History HIV , Hepatitis B , Hepatitis C Surgery within 6 month screen Donation loss &gt; 400 mL blood blood product within 8 week prior start study Use proteins antibody within 12 week prior screen . ( Flu shot allow . ) Exposure investigational agent participation investigational trial within 30 day start study History drug alcohol abuse within 12 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>